Clinical Research Directory

Inclusion Criteria: * Histopathologically confirmed, previously untreated DLBCL; * Age ≥70 years, or ≥60 years with comorbidities (including reduced left ventricular ejection fraction, history of myocardial infarction \[\>6 months prior to enrollment\], exertional angina, arrhythmia \[Grade ≤2\], hypertension or diabetes requiring treatment), or ECOG PS ≥2 deemed ineligible for standard chemotherapy; * At least one measurable lesion, defined as: Nodal lesion: Longest diameter \>1.5 cm, or Extranodal lesion: Longest diameter \>1.0 cm, with two perpendicular dimensions accurately measurable; * ECOG PS ≤3; * Estimated life expectancy ≥3 months * MYC and BCL2 protein co-expression confirmed by immunohistochemistry (double-expressor lymphoma) * Voluntary participation; full understanding of the study with signed informed consent; willingness and ability to comply with all study procedures Exclusion Criteria: * Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception; * Recipients of organ transplantation; * Uncontrolled coagulopathy or active bleeding; * Uncontrolled cardiocerebrovascular diseases (including LVEF \<50%), connective tissue diseases, or severe active infections; * Major organ surgery within 6 weeks prior to screening; * Laboratory abnormalities at screening (unless lymphoma-related): Neutrophils \<1.5×10⁹/L; Platelets \<80×10⁹/L (\<50×10⁹/L if bone marrow involvement); Liver dysfunction: Total bilirubin \>1.5×ULN, ALT/AST \>2.5×ULN (or \>5×ULN with liver involvement); Renal dysfunction: Serum creatinine \>1.5×ULN; * HBV infection: HBsAg-positive patients: Eligible if HBV DNA \<10³ IU/mL; HBsAg-negative but HBcAb-positive (regardless of HBsAb status): Eligible if HBV DNA \<10³ IU/mL; * HIV infection; * Central nervous system lymphoma involvement; * Concurrent antitumor therapy (for lymphoma or other malignancies); * Substance abuse or chronic alcoholism affecting outcome evaluation; * Psychiatric disorders or other conditions compromising protocol compliance; * Concurrent use of strong/moderate CYP3A4 inhibitors/inducers: Excluded if taken within 7 days prior to treatment (or \<5 half-lives); * Inability to swallow capsules or significant gastrointestinal dysfunction (e.g., malabsorption, bariatric surgery, IBD, bowel obstruction); * Other uncontrolled conditions deemed by investigators to: Jeopardize patient safety; Interfere with drug absorption/metabolism; Pose excessive risk to study outcomes